Skip to main content
. 2008 Oct 16;38(11):777–785. doi: 10.1093/jjco/hyn101

Table 4.

Grades 3 and 4 adverse drug reactions

Adverse Reaction (MedDRA/J Ver9.0) Number of patients (n = 74)
Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Neutropenia 8 (10.8) 11 (14.9) 23 (31.1) 27 (36.5)
Lymphocytopenia 15 (20.3) 16 (21.6) 29 (39.2) 6 (8.1)
Leukopenia 5 (6.8) 20 (27.0) 39 (52.7) 5 (6.8)
Haemoglobin decreased 23 (31.1) 27 (36.5) 11 (14.9) 2 (2.7)
Thrombocytopenia 27 (36.5) 13 (17.6) 4 (5.4) 1 (1.4)
Deep vein thrombosis 0 (0) 0 (0) 0 (0) 1 (1.4)
Hand-foot syndrome 20 (27.0) 26 (35.1) 12 (16.2) 0 (0)
Stomatitis 29 (39.2) 22 (29.7) 6 (8.1) 0 (0)
Erythropenia 42 (56.8) 11 (14.9) 3 (4.1) 0 (0)
Nausea 37 (50.0) 6 (8.1) 2 (2.7) 0 (0)
ALT (GPT) increased 16 (21.6) 1 (1.4) 2 (2.7) 0 (0)
Blood potassium decreased 10 (13.5) 0 (0) 2 (2.7) 0 (0)
Febrile neutropenia 0 (0) 0 (0) 2 (2.7) 0 (0)
Rash 17 (23.0) 19 (25.7) 1 (1.4) 0 (0)
Fatigue 28 (37.8) 5 (6.8) 1 (1.4) 0 (0)
Vomiting 11 (14.9) 5 (6.8) 1 (1.4) 0 (0)
γ-GTP increased 13 (17.6) 4 (5.4) 1 (1.4) 0 (0)
Diarrhoea 12 (16.2) 4 (5.4) 1 (1.4) 0 (0)
AST (GOT) increased 18 (24.3) 2 (2.7) 1 (1.4) 0 (0)
Upper respiratory tract infection 0 (0) 2 (2.7) 1 (1.4) 0 (0)
Blood sodium decreased 15 (20.3) 0 (0) 1 (1.4) 0 (0)
Small intestinal obstruction 0 (0) 0 (0) 1 (1.4) 0 (0)
Herpes zoster 0 (0) 0 (0) 1 (1.4) 0 (0)
Infection 0 (0) 0 (0) 1 (1.4) 0 (0)
Glucose tolerance impaired 0 (0) 0 (0) 1 (1.4) 0 (0)